Search is Powered by Google
Statins News

Removal Of Black Triangle Status For Crestor, UK

Main Category: Statins
Also Included In: Cholesterol;  Cardiovascular / Cardiology
Article Date: 22 Jun 2007 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

4 (3 votes)

Health Professional:3 stars

3 (2 votes)

Article Opinions: 0 posts

Following a comprehensive analysis of the pre and post marketing data by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) the risk/benefit profile for rosuvastatin (CRESTOR) has been confirmed and black triangle status has been removed for rosuvastatin.

What Does This Mean For Health Care Professionals?

New medicines are marked with an inverted black triangle symbol to encourage the medicine to be intensively monitored in order to confirm its pre- marketing risk/benefit profile in real life. The CHM and the MHRA therefore encourage health care professionals to report all suspected reactions to black triangle medicines through the yellow-card scheme. When the CHM and MHRA are satisfied that the benefit/risk profile for the medicine established during the pre-marketing phase has been confirmed, the black triangle status is removed and Healthcare Professionals are no longer required to report suspected non-serious adverse drug reactions through the yellow card system1. Therefore:

Rosuvastatin no longer has black triangle status because the benefit/risk profile has been confirmed by the MHRA and CHM. Health Care Professionals ( HCPs) are no longer required to report suspected non-serious rosuvastatin adverse events through the yellow card system.

In line with other established medicines, HCPs are now only required to report suspected serious adverse drug reactions* (and are no longer required to report non-serious adverse drug reactions) through the yellow card system.

AstraZeneca is committed to ensuring optimum patient care and proactively monitors the experience and use for all of its medicines on an ongoing basis.

* Definition of serious adverse drug reaction1: Serious reactions include those that are:

-- fatal;
-- life-threatening;
-- disabling or incapacitating;
-- result in or prolong hospitalisation;
-- congenital abnormalities; or
-- medically significant.

Rosuvastatin (CRESTOR®) 5-40mg

-- Rosuvastatin is available in 5mg-40mg dose range. The recommended start dose of rosuvastatin is 5 or 10mg2

-- The majority of patients achieve their LDL-cholesterol goal with rosuvastatin 10mg3-4

-- If necessary, dose adjustment to rosuvastatin 20mg can be made. Patients with severe hypercholesterolemia and at high cardiovascular risk who do not achieve their LDL-cholesterol goal with rosuvastatin 20mg may be titrated to the maximum dose of rosuvastatin 40mg2

-- Specialist supervision is recommended when the 40mg dose is initiated2

-- Rosuvastatin 20mg is the maximum dose to be used with concomitant fibrate usage; in patients with predisposing factors for developing myopathy/rhabdomyolysis; and in patients of Asian origin2

-- The 40 mg dose is the highest registered dose of rosuvastatin2. Rosuvastatin should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile.

References:

1. Medicines and Healthcare Products Regulatory Agency (MRHA). New drugs and vaccines under intensive surveillance. http://www.mhra.gov.uk accessed June, 2007

2. Crestor SmPC http://www.medicines.org.uk

3. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. American Heart Journal 2004; 147: 705-712

4. Middleton A et al. Achieving lipid goals in real life: the DISCOVERY-UK study. The British Journal of Cardiology 2006;13:72-76

AstraZeneca

View drug information on Crestor.





Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Omega-3 Polyunsaturated Fatty Acids Reduce Mortality And Hospital Admission In Patients With Heart Failure, Statins Show No Effect
31 Aug 2008
A simple, safe, one-a-day capsule of omega-3 polyunsaturated fatty acids (PUFA) can reduce mortality and admission to hospital for cardiovascular reasons in patients with heart failure...


Learning to Stretch the Right Way
Learning to Stretch the Right Way

Knowing the right way to stretch can prevent injury and help you make the most out of your workout.

more videos are available in our health videos section.